Literature DB >> 9840284

Functional analysis of the proximal CCR5 promoter.

R Liu1, X Zhao, T A Gurney, N R Landau.   

Abstract

Two promoters for the CCR5 gene, termed Pu and Pd, corresponding to the upstream and downstream initiation sites, respectively, have been described. We show here that the proximal promoter, Pd, is used two- to fivefold more frequently than Pu in primary activated T cells and in the transformed T cell line PM1. Because of its importance in CCR5 transcription we characterized the transcriptional activity of this promoter. Pd contains a pair of consensus TATA elements (nt -19 and -31) and several potential regulatory elements and transcription factor-binding sites, including those for STAT, NF-kappaB, AP-1, NF-AT, and CD28RE. Using a transfected reporter vector, we found the promoter to be highly active and cell type specific. By 5' deletion analysis, the minimal CCR5 promoter was localized to a 225-nucleotide region (nt -189 to +36). This region contained the two TATA elements, a CD28RE consensus sequence, an AP-1-binding site, and two STAT-binding sites. The 1.9-kb intron appeared to have a negative influence on reporter gene activity, suggesting the presence of a negative element in this region. In addition, an upstream negative element was detected in the region nt -988 to -588. Mutagenesis of the TATA elements, of the NF-kappaB-, and AP-1-, and STAT-binding sites, and of the CD28RE indicated the importance of each of these in transcription. Finally, the NF-kappaB/Rel family member, p65(RelA), was a potent activator of the CCR5 promoter.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9840284     DOI: 10.1089/aid.1998.14.1509

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  23 in total

1.  VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.

Authors:  Blythe C Dillingham; Susan M Knoblach; Gina M Many; Brennan T Harmon; Amanda M Mullen; Christopher R Heier; Luca Bello; John M McCall; Eric P Hoffman; Edward M Connor; Kanneboyina Nagaraju; Erica K M Reeves; Jesse M Damsker
Journal:  Cell Mol Neurobiol       Date:  2014-11-13       Impact factor: 5.046

2.  Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes.

Authors:  J P Lai; W Z Ho; G X Zhan; Y Yi; R G Collman; S D Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

3.  CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects.

Authors:  Qingwen Jin; Lokesh Agrawal; L Meyer; R Tubiana; Ioannis Theodorou; Ghalib Alkhatib
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

4.  Transcriptional regulation of the chemokine co-receptor CCR5 by the cAMP/PKA/CREB pathway.

Authors:  Anupam Banerjee; Vanessa Pirrone; Brian Wigdahl; Michael R Nonnemacher
Journal:  Biomed Pharmacother       Date:  2011-05-30       Impact factor: 6.529

5.  The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.

Authors:  J Claire Godbersen; Leigh Ann Humphries; Olga V Danilova; Peter E Kebbekus; Jennifer R Brown; Alan Eastman; Alexey V Danilov
Journal:  Clin Cancer Res       Date:  2014-03-15       Impact factor: 12.531

6.  CCR5, MCP-1 and VDR Gene Polymorphisms Are Associated with the Susceptibility to HBV Infection.

Authors:  Bita Moudi; Zahra Heidari; Hamidreza Mahmoudzadeh-Sagheb
Journal:  Indian J Clin Biochem       Date:  2018-06-27

7.  IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivo.

Authors:  Cheryl A Stoddart; Mary E Keir; Joseph M McCune
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

8.  Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.

Authors:  Olga Latinovic; Janaki Kuruppu; Charles Davis; Nhut Le; Alonso Heredia
Journal:  Clin Med Ther       Date:  2009

9.  Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection.

Authors:  Max W Richardson; Julie Jadlowsky; Chuka A Didigu; Robert W Doms; James L Riley
Journal:  J Immunol       Date:  2012-09-17       Impact factor: 5.422

10.  The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation.

Authors:  Gero Hütter; Martin Neumann; Daniel Nowak; Stefan Klein; Harald Klüter; Wolf-K Hofmann
Journal:  J Inflamm (Lond)       Date:  2011-10-26       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.